Research

Adherence

At a population level, distributing GLP-1 medications using extended dosing intervals (q2wk) allows twice as many obese adults to be treated for the same total cost, leading to greater reductions in national obesity rates and mortality.

For policymakers and insurers, extending GLP-1 dosing intervals to every two weeks allows the same budget to treat twice as many people. While each individual might lose slightly less weight, the overall public health benefit (reduced obesity and mortality) is significantly higher. This is a key strategy for making these drugs accessible at a national scale.

LimitedSupportsLOW confidence
our analysis suggests that (2) reduces national obesity and mortality to a much greater degree.
Anıl Cengiz et al. · Diabetes Obesity and Metabolism · 2025

Why this rating

Based on mathematical modeling and simulation of national health data.

Source

Alternative dosing regimens of <scp>GLP</scp> ‐1 receptor agonists may reduce costs and maintain weight loss efficacy

Anıl Cengiz et al. · Diabetes Obesity and Metabolism · 2025

DOI 10.1111/dom.16229

preprintCited 13×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →